We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00766116
First Posted: October 3, 2008
Last Update Posted: August 15, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Celgene Corporation
Pfizer
Information provided by (Responsible Party):
Edward Ball, University of California, San Diego
  Purpose
This study will test an experimental combination of the drugs Mylotarg and 5-azacitidine in the hopes of finding a treatment that may be effective against Acute Myeloid Leukemia that has come back after treatment.

Condition Intervention Phase
Acute Myeloid Leukemia Drug: 5-Azacitidine Drug: Gemtuzumab ozogamicin Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed AML

Resource links provided by NLM:


Further study details as provided by Edward Ball, University of California, San Diego:

Primary Outcome Measures:
  • In Phase I the Maximum Tolerated Dose will be the maximum dose at which fewer than one-third of patients experience Dose Limiting Toxicity [ Time Frame: approximately 4 years ]

Secondary Outcome Measures:
  • In Phase II response to the combination treatment of Mylotarg with 5-azacitidine [ Time Frame: Response will be assessed when evaluated at the time the ANC has reached 1000/mm3 for three consecutive days ]

Enrollment: 50
Study Start Date: July 2005
Estimated Study Completion Date: December 2017
Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment
5-Azacitidine, Gemtuzumab ozogamicin
Drug: 5-Azacitidine
A = given in cohorts of 3 starting with 2 doses of 5-azacitidine. The doses of 5-azacitidine will be escalated to 4 and then 6 doses if the dose escalation rules permit
Other Name: Vidaz
Drug: Gemtuzumab ozogamicin
M = Mylotarg given 2 times over 2 weeks
Other Name: Mylotarg

Detailed Description:

In the Phase I portion of the study patients with a diagnosis of AML who have relapsed disease will be treated with an assigned number of doses of 5 azacitidine followed by Mylotarg administered two times over two weeks

In the Phase II portion of the study patients will be treated with the dose of 5azacitidine determined to be safe in the Phase I portion of the study followed by Mylotarg.

A sample of blood or bone marrow will be obtained prior to initiation of treatment and another sample obtained after treatment with 5-azacitidine but before Mylotarg and the samples will be tested in the laboratory to determine response to treatment.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Relapsed AML
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2, and life expectancy > 3 months
  • ≥ 18 years old
  • Previously untreated for current AML relapse
  • Adequate organ function
  • Written informed consent

Exclusion Criteria:

  • Pregnant or breast-feeding women
  • Growth factors that support platelet or white cell number or function must not have been administered within the past 7 days
  • Currently receiving another investigational drug
  • Currently receiving other anti-cancer agents
  • Uncontrolled infection
  • HIV positive
  • Received previous therapy with either Mylotarg or 5-azacitidine
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00766116


Locations
United States, California
UCSD Moores Cancer Center
La Jolla, California, United States, 92093
Stanford University
Stanford, California, United States, 94305
United States, Georgia
Northside Hospital/BMTGA
Atlanta, Georgia, United States, 30342
Sponsors and Collaborators
University of California, San Diego
Celgene Corporation
Pfizer
Investigators
Principal Investigator: Edward D Ball, MD UCSD
  More Information

Responsible Party: Edward Ball, Professor of medicine, University of California, San Diego
ClinicalTrials.gov Identifier: NCT00766116     History of Changes
Other Study ID Numbers: 090516
First Submitted: October 2, 2008
First Posted: October 3, 2008
Last Update Posted: August 15, 2017
Last Verified: August 2017

Keywords provided by Edward Ball, University of California, San Diego:
AML

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms
Azacitidine
Gemtuzumab
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors